A Null Mutation in Human APOC3 Confers a Favorable Plasma Lipid Profile and Apparent Cardioprotection

Apolipoprotein C-III (apoC-III) inhibits triglyceride hydrolysis and has been implicated in coronary artery disease. Through a genome-wide association study, we have found that about 5% of the Lancaster Amish are heterozygous carriers of a null mutation (R19X) in the gene encoding apoC-III (APOC3) a...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Pollin, Toni I., Damcott, Coleen M., Shen, Haiqing, Ott, Sandra H., Shelton, John, Horenstein, Richard B., Post, Wendy, McLenithan, John C., Bielak, Lawrence F., Peyser, Patricia A., Mitchell, Braxton D., Miller, Michael, O'Connell, Jeffrey R., Shuldiner, Alan R.
Format: Artigo
Langue:Inglês
Publié: 2008
Sujets:
Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC2673993/
https://ncbi.nlm.nih.gov/pubmed/19074352
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1126/science.1161524
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires